[1]袁小强,张献朝,赵丽萍.西那卡塞和骨化三醇联合治疗糖尿病肾病血液透析患者继发性甲状旁腺功能亢进症疗效观察[J].新乡医学院学报,2022,39(2):131-135.[doi:10.7683/xxyxyxb.2022.02.006]
　YUAN Xiaoqiang,ZHANG Xianchao,ZHAO Liping.Effect of cinacalcet and calcitriol in the treatment of secondary hyperparathyroidism in diabetic nephropathy patients undergoing hemodialysis[J].Journal of Xinxiang Medical University,2022,39(2):131-135.[doi:10.7683/xxyxyxb.2022.02.006]
点击复制

西那卡塞和骨化三醇联合治疗糖尿病肾病血液透析患者继发性甲状旁腺功能亢进症疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年2
页码:
131-135
栏目:
临床研究
出版日期:
2022-02-05

文章信息/Info

Title:
Effect of cinacalcet and calcitriol in the treatment of secondary hyperparathyroidism in diabetic nephropathy patients undergoing hemodialysis
作者:
袁小强; 张献朝; 赵丽萍
（平顶山市第一人民医院肾脏病风湿免疫科，河南　平顶山　467000）
Author(s):
YUAN Xiaoqiang; ZHANG Xianchao; ZHAO Liping
(Department of Nephrology and Rheumatology and Immunology,the First People′s Hospital of Pingdingshan City,Pingdingshan 467000,Henan Province,China)
关键词:
糖尿病肾病; 继发性甲状旁腺功能亢进; 西那卡塞; 骨化三醇; 血液透析
Keywords:
diabetic nephropathy; secondary hyperparathyroidism; cinacalcet; calcitriol; hemodialysis
分类号:
R582
DOI:
10.7683/xxyxyxb.2022.02.006
文献标志码:
A
摘要:
目的　探讨西那卡塞和骨化三醇联合治疗糖尿病肾病（DN）血液透析患者继发性甲状旁腺功能亢进症（SHPT）的临床效果。方法　选择2018年6月至2020年4月平顶山市第一人民医院收治的128例DN血液透析SHPT患者为研究对象，根据治疗方案将患者分为观察组和对照组，每组64例。2组患者均给予碳酸氢盐透析液标准化血液透析治疗，在血液透析治疗基础上，对照组患者给予盐酸西那卡塞片治疗，观察组患者给予盐酸西那卡塞片和骨化三醇联合治疗，2组患者均治疗6个月。治疗前及治疗3、6个月，检测2组患者血钙、血磷、血尿素氮（BUN）、血肌酐（Scr）及血清骨保护素（OPG）、成纤维细胞生长因子23（FGF-23）、全段甲状旁腺激素（iPTH）水平，采用尿素动力学模式计算尿素清除指数（KT/V），应用颈部超声波测量甲状旁腺体积。治疗6个月后评估2组患者的临床疗效，治疗期间观察2组患者不良反应发生情况。结果　2组患者治疗前血钙、血磷水平及钙磷乘积比较差异无统计学意义（P>0.05）；2组患者治疗3、6个月后血钙水平显著高于治疗前，血磷水平、钙磷乘积显著低于治疗前（P<0.05）；2组患者治疗6个月后血钙水平显著高于治疗3个月，血磷水平、钙磷乘积显著低于治疗3个月（P<0.05）；治疗3、6个月后，观察组患者血钙水平显著高于对照组，血磷水平、钙磷乘积显著低于对照组（P<0.05）。2组患者治疗前血清OPG、FGF-23水平比较差异无统计学意义（P>0.05）；2组患者治疗3、6个月后血清OPG、FGF-23水平显著低于治疗前（P<0.05），2组患者治疗6个月后血清OPG、FGF-23水平显著低于治疗3个月（P<0.05）；治疗3、6个月后，观察组患者血清OPG、FGF-23水平显著低于对照组（P<0.05）。2组患者治疗前BUN、Scr水平及KT/V比较差异无统计学意义（P>0.05）；2组患者治疗3、6个月后BUN、Scr水平及KT/V与治疗前比较差异无统计学意义（P>0.05）；2组患者治疗6个月后BUN、Scr水平及KT/V与治疗3个月后比较差异无统计学意义（P>0.05）；治疗3、6个月后，2组患者BUN、Scr水平及KT/V比较差异无统计学意义（P>0.05）。2组患者治疗前甲状旁腺体积、血清iPTH水平比较差异无统计学意义（P>0.05）；2组患者治疗3、6个月后甲状旁腺体积、血清iPTH水平显著低于治疗前（P<0.05），2组患者治疗6个月后甲状旁腺体积、血清iPTH水平显著低于治疗3个月（P<0.05）；治疗3、6个月后，观察组患者甲状旁腺体积、血清iPTH水平显著低于对照组（P<0.05）。观察组和对照组患者治疗总有效率分别为93.75%（60/64）、81.25%（52/64），观察组患者治疗总有效率显著高于对照组（χ2=4.571，P<0.05）。观察组和对照组患者不良反应发生率分别为10.94%（7/64）、7.81%（5/64），2组患者不良反应发生率比较差异无统计学意义（χ2=0.368，P>0.05）。结论　西那卡塞和骨化三醇联合治疗可以有效调节DN血液透析SHPT患者的血清iPTH水平，改善骨代谢和钙磷代谢紊乱，缩小甲状旁腺体积。
Abstract:
Objective　To investigate the effect of cinacalcet and calcitriol in the treatment of secondary hyperparathyroidism(SHPT) in diabetic nephropathy(DN) patients undergoing hemodialysis.Methods　A total of 128 DN complicated with SHPT patients who underwent hemodialysis in the First People′s Hospital of Pingdingshan City from June 2018 to April 2020 were selected as the research subjects,and the patients were divided into observation group and control group according to the treatment plan,with 64 cases in each group.The patients in the both groups were treated with bicarbonate dialysate standardized hemodialysis.On the basis of hemodialysis,the patients in the control group were treated with cinacalcet hydrochloride tablets,and the patients in the observation group were treated with cinacalcet hydrochloride tablets and calcitriol.The patients in the both groups were treated for six months.Before treatment and after 3 and 6 months of treatment,the levels of blood calcium calcium,blood phosphorus,blood urea nitrogen (BUN) and serum creatinine (Scr),osteoprotegerin (OPG),fibroblast growth factor 23 (FGF-23),intact parathyroid hormone (iPTH) were detected.The urea clearance index (KT/V) was calculated by urea kinetic model,and the volume of parathyroid gland was measured by neck ultrasound.The clinical efficacy of patients in the two groups was evaluated after 6 months of treatment,and the adverse reactions of patients in the two groups were observed during the treatment.Results　There was no significant difference in blood calcium,phosphorus levels and calcium-phosphorus product between the two groups before treatment (P>0.05).Compared with before treatment,the blood calcium level of patients in the two groups was significantly increased after 3 and 6 months of treatment,and the blood phosphorus level and calcium-phosphorus product were significantly decreased (P<0.05).Compared with 3 months of treatment,the blood calcium level of patients in the two groups was significantly increased after 6 months of treatment,and the blood phosphorus level and calcium-phosphorus product was significantly decreased (P<0.05).After 3 and 6 months of treatment,the serum calcium level of patients in the observation group was significantly higher than that in the control group,and the blood phosphorus level and calcium-phosphorus product were significantly lower than those in the control group (P<0.05).There was no significant difference in serum OPG and FGF-23 levels between the two groups before treatment (P>0.05).The levels of serum OPG and FGF-23 in the two groups after 3 and 6 months of treatment were significantly lower than those before treatment (P<0.05).The levels of serum OPG and FGF-23 in the two groups after 6 months of treatment were significantly lower than those after 3 months of treatment (P<0.05).The levels of serum OPG and FGF-23 in the observation group were significantly lower than those in the control group after 3 and 6 months of treatment (P<0.05).There was no significant difference in the levels of BUN,Scr and KT/V between the two groups before treatment (P>0.05).There was no significant difference in the levels of BUN,Scr and KT/V between 3,6 months of treatment and before treatment in the two groups (P>0.05).There was no signifi-cant difference in the levels of BUN,Scr and KT/V of patients in the two groups between 6 months of treatment and 3 months of treatment (P>0.05).There was no significant difference in the levels of BUN,Scr and KT/V of patients between the two groups after 3 and 6 months of treatment (P>0.05).There was no significant difference in parathyroid volume and serum iPTH level between the two groups before treatment (P>0.05).The parathyroid volume and serum iPTH level of patients in the two groups after 3 and 6 months of treatment were significantly lower than those before treatment (P<0.05).The volume of parathyroid glands and serum iPTH level in the two groups after 6 months of treatment were significantly lower than those after 3 months of treatment (P<0.05).The parathyroid volume and serum iPTH level in the observation group were significantly lower than those in the control group after 3 and 6 months of treatment (P<0.05).The total effective rate of patients in the observation group and control group was 93.75% (60/64) and 81.25% (52/64),respectively.The total effective rate in the observation group was significantly higher than those in the control group (χ2=4.571,P<0.05).The incidence of adverse reactions in the observation group and control group was 10.94%(7/64) and 7.81%(5/64),respectively.There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.368,P>0.05).Conclusion　The combined treatment of cinacalcet and calcitriol can effectively regulate the serum iPTH level in DN patients with SHPT who underwent hemodialysis,improve bone metabolism and calcium and phosphorus metabolism disorders,and reduce the volume of parathyroid.

参考文献/References:

［1］　LEVY A R,XING S,BRUNELLI S M,et al.Symptoms of secondary hyperparathyroidism in patients receiving maintenance hemodialysis:a prospective cohort study［J］.Am J Kidney Dis,2020,75(3):373-383.
［2］　贺西南，石宏斌.慢性肾脏病继发性甲状旁腺功能亢进的研究进展［J］.中国中西医结合肾病杂志，2019，20（5）：456-459.
HE X N,SHI H B.Research progress of secondary hyperparathyroidism in chronic kidney disease［J］.CJITWN,2019,20(5):456-459.
［3］　许颖波，马瑜智，张娟，等.西那卡塞治疗血液透析患者继发性甲状旁腺功能亢进症的临床研究［J］.基因组学与应用生物学，2020，39（1）：295-302.
XU Y B,MA Y Z,ZHANG J,et al.Clinical study of sinakase in the treatment of secondary hyperparathyroidism in hemodialysis patients［J］.Genom Appl Biol,2020,39(1):295-302.
［4］　ZHANG T,JU H B,CHEN H J,et al.Comparison of paricalcitol and calcitriol in dialysis patients with secondary hyperparathyroidism:a meta-analysis of randomized controlled studies［J］.Ther Apher Dial,2019,23(1):73-79.
［5］　中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识（2014年版）［J］.中华糖尿病杂志，2014，6（11）：792-801.
MICROVASCULAR COMPLICATIONS GROUP OF DIABETES ASSOCIATION OF CHINESE MEDICAL ASSOCIATION.Expert consensus on prevention and treatment of diabetic nephropathy 2014［J］.Chin J Diabetes Mellitus,2014,6(11):792-801.
［6］　NATIONAL KIDNEY FOUNDATION.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease［J］.Am J Kidney Dis,2003,42(4 Suppl 3):S1-S201.
［7］　COZZOLINO M,MESSA P.Treatments for secondary hyperparathyroidism in hemodialysis［J］.Pol Arch Intern Med,2017,127(12):807-809.
［8］　孙桂江，魏芳，于海波，等.西那卡塞联合骨化三醇治疗维持性血液透析合并继发性甲状旁腺功能亢进患者的疗效观察［J］.中华全科医师杂志，2018，17（9）：717-720.
SUN G J,WEI F,YU H B,et al.Efficacy of sinakase combined with calcitriol in the treatment of maintenance hemodialysis patients with secondary hyperparathyroidism［J］.Chin J Gen Pract,2018,17(9):717-720.
［9］　周凌辉，张恒远，裴娟，等.长疗程西那卡塞治疗维持性血液透析患者难治性继发性甲状旁腺功能亢进症的临床观察［J］.中国全科医学，2018，21（8）：989-992.
ZHOU L H,ZHANG H Y,PEI J,et al.Clinical efficacy of long-term cinacalcet treatment for refractory secondary hyperparathyroidism in maintenance hemodialysis patients［J］.Chin Gen Pract,2018,21(8):989-992.
［10］　王垚，于博，魏巍，等.西那卡塞联合小剂量骨化三醇治疗血液透析患者继发性甲状旁腺功能亢进的疗效观察［J］.中国中西医结合肾病杂志，2018，19（5）：435-437.
WANG Y,YU B,WEI W,et al.Efficacy of sinakase combined with low-dose calcitriol in the treatment of secondary hyperparathyroidism in hemodialysis patients［J］.CJITWN,2018,19(5):435-437.
［11］　RUDERMAN I,SMITH E R,TOUSSAINT N D,et al.Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism［J］.BMC Nephrol,2018,19(1):113.
［12］　MA Q,SU D C,LIU F,et al.Parathyroidectomy influences coronary artery calcium score in asymptomatic hemodialysis patients with secondary hyperparathyroidism［J］.Am J Nephrol,2020,51(1):65-73.
［13］　师红红，张翠芳，吕程，等.甲状旁腺切除术后维持性血液透析患者腹主动脉钙化及骨代谢指标改变［J］.中国血液净化，2019，18（1）：1-7.
SHI H H,ZHANG C F,LYU C,et al.Changes of abdominal aortic calcification and bone metabolism after parathyroidectomy in maintenance hemodialysis patients［J］.Chin J Blood Purif,2019,18(1):1-7.
［14］　胡顺金，曹媛茹，王东，等.蓉黄颗粒对非透析肾虚湿热证慢性肾脏病矿物质和骨异常患者血清OPG、RANKL水平的影响［J］.中国免疫学杂志，2018，34（5）：693-698.
HU S J,CAO Y R,WANG D,et al.Effect of Ronghuang granules on serum OPG and RANKL levels in patients with mineral and bone abnormalities of chronic kidney disease with non dialysis kidney deficiency damp heat syndrome［J］.Chin J Immunol,2018,34(5):693-698.
［15］　MIHAI R,SITGES-SERRA A.Multigland primary hyperparathyroidism:frequently considered,seldom encountered［J］.Langenbecks Arch Surg,2015,400(8):863-866.

相似文献/References:

[1]袁慧娟　翁孝刚　窦敬芳　郭永年.芎嗪对实验性糖尿病大鼠肾脏的保护作用[J].新乡医学院学报,1999,16(04):331.
[2]乔立新,张兴国,熊芬霞,等.益气活血胶囊的制备及其治疗Ⅱ型糖尿病的疗效[J].新乡医学院学报,2001,18(06):404.
[3]翁孝刚． 赵誉洲,陈三敏,越志勇． 郭永年.川芎嗪、山茛菪碱、蝮蛇抗栓酶及卡托普利对糖尿病大鼠肾脏的保护作用[J].新乡医学院学报,2001,18(01):020.
[4]杨福燕,魏崇一,王凤业,等.阿魏酸钠对糖尿病肾病患者血浆内皮素的影响[J].新乡医学院学报,2003,20(03):199.
[5]杨福燕,魏崇一,王凤业,等.阿魏酸钠对糖尿病肾病患者血浆内皮素的影响[J].新乡医学院学报,2003,20(03):199.
[6]王晓青,李　竞,王鹏虎.氯沙坦联合苯那普利对早期糖尿病肾病患者血清TGF2β1 及MCP21的影响[J].新乡医学院学报,2006,23(05):517.
[7]游然,张同帅.奥扎格雷钠治疗糖尿病肾病疗效观察 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):382.
[8]谭静.糖尿病肾病患者血清C 反应蛋白、肿瘤坏死因子-α 和血管内皮生长因子水平变化[J].新乡医学院学报,2012,29(09):678.
[9]崔艳,赵晓露,师晶晶,等.梅花鹿鹿茸总蛋白对糖尿病肾病大鼠肾损伤的治疗作用及分子机制[J].新乡医学院学报,2023,40(1):011.[doi:10.7683/xxyxyxb.2023.01.002]
　CUI Yan,ZHAO Xiaolu,SHI Jingjing,et al.Therapeutic effect and molecular mechanism of Sika deer velvet antler protein on renal injury of rats with diabetes nephropathy[J].Journal of Xinxiang Medical University,2023,40(2):011.[doi:10.7683/xxyxyxb.2023.01.002]
[10]阎婷婷,赵英政,易宪文,等.氧化应激及炎症对糖尿病肾病的影响[J].新乡医学院学报,2019,36(8):701.[doi:10.7683/xxyxyxb.2019.08.001]

更新日期/Last Update: 2022-02-05